Anticancer Drugs Nilotinib Oncology Pharmacology Physiotherapy

Nilotinib (Side Effects)

In this article we will discuss Nilotinib (Side Effects)

In this article, we will discuss Nilotinib (Side Effects). So, let’s get started.

Adverse Reactions

The following clinically significant adverse reactions can occur with Nilotinib (Tasigna®) and are discussed below:

• Myelosuppression
• QT Prolongation
• Sudden Deaths
• Cardiac and Arterial Vascular Occlusive Events
• Pancreatitis and Elevated Serum Lipase
• Hepatotoxicity
• Electrolyte Abnormalities
• Hemorrhage
• Fluid Retention

Warnings and Precautions

Myelosuppression: Monitor complete blood count (CBC) during therapy and manage by treatment interruption or dose reduction.
Cardiac and Arterial Vascular Occlusive Events: Evaluate cardiovascular status, monitor and manage cardiovascular risk factors during Nilotinib (Tasigna®) therapy.
Pancreatitis and Elevated Serum Lipase: Monitor serum lipase, if elevations are accompanied by abdominal symptoms, interrupt doses and consider appropriate diagnostics to exclude pancreatitis.
Hepatotoxicity: Monitor hepatic function tests monthly or as clinically indicated.
Electrolyte Abnormalities: Nilotinib (Tasigna®) can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Correct electrolyte abnormalities prior to initiating Nilotinib (Tasigna®) and monitor periodically during therapy.
Tumor Lysis Syndrome: Maintain adequate hydration and correct uric acid levels prior to initiating therapy with Nilotinib (Tasigna®).
Hemorrhage: Hemorrhage from any site may occur. Advise patients to report signs and symptoms of bleeding and medically manage as needed.
Fluid Retention: Monitor patients for unexpected rapid weight gain, swelling, and shortness of breath. Manage medically.
Effects on Growth and Development in Pediatric Patients: Growth retardation has been reported in pediatric patients treated with Nilotinib (Tasigna®). Monitor growth and development in pediatric patients.
Embryo-Fetal Toxicity: Advise patients of potential risk to a fetus and to use effective contraception.
Treatment Discontinuation: Patients must have typical BCR-ABL transcripts. An FDA-authorized test with a detecuon limit below MR4.5 must be used to determine eligibility for discontinuation. Patients must be frequently monitored by the FDA authorized test to detect possible loss of remission.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.